Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
This retrospective observational study is aimed to determine the efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac (Sinovac) vaccines against symptomatic or severe disease in COVID-19-diagnosed patients. The secondary aim was to define the differences between vaccinated and un-vaccinated patients...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2023-06-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2023-0020 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832569998559674368 |
|---|---|
| author | Dogan Mustafa Yilmaz Berna |
| author_facet | Dogan Mustafa Yilmaz Berna |
| author_sort | Dogan Mustafa |
| collection | DOAJ |
| description | This retrospective observational study is aimed to determine the efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac (Sinovac) vaccines against symptomatic or severe disease in COVID-19-diagnosed patients. The secondary aim was to define the differences between vaccinated and un-vaccinated patients in terms of age, comorbidities and course of the disease, and to determine the survival rates. Of the 1463 PCR-positive patients, 55.3 % were vaccinated, and 44.7 % were unvaccinated. While 959 patients had mild-moderate symptoms, 504 patients had severe-critical symptoms and were treated in the intensive care unit. There was a statistically significant difference in the distribution of the type and doses of vaccines between the patient groups (p = 0.021). The rate of receiving 2 doses of Biontech was 18.9 % in the mild-moderate patient group but lower in the severe patient group (12.6 %). The rate of two doses of Sinovac and two doses of Biontech vaccine (four doses of vaccine) was 5 % in the mild-moderate patient group and 1.9 % in the severe patient group. The mortality rates were statistically significantly different (p < 0.001) between the patient groups: 65.3 % in the severe patient group and 1 % in the mild-moderate patient group. The multivariate model showed that the mortality risk of the unvaccinated patients was 1.5 times higher than the vaccinated ones (p = 0.042). In addition to being unvaccinated, advanced age, coronary artery disease (CAD), diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), and obesity were found to be associated with higher mortality risk. Besides, the reduction in mortality rate was more evident in individuals vaccinated with at least 2 doses of the BNT162b2 (Pfizer-BioNTech) vaccine than in CoronaVac group. |
| format | Article |
| id | doaj-art-5540e562e1094d4691d0fbcce8ed8340 |
| institution | Kabale University |
| issn | 1846-9558 |
| language | English |
| publishDate | 2023-06-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-5540e562e1094d4691d0fbcce8ed83402025-02-02T17:57:33ZengSciendoActa Pharmaceutica1846-95582023-06-0173225726810.2478/acph-2023-0020Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19Dogan Mustafa0Yilmaz Berna11Tekirdag Corlu State Hospital Department of Infection Diseases and Clinical MicrobiologyTekirdag, 59850Turkey2Manisa City Hospital Department of Anesthesiology Reanimation and Intensive Care Manisa, TurkeyThis retrospective observational study is aimed to determine the efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac (Sinovac) vaccines against symptomatic or severe disease in COVID-19-diagnosed patients. The secondary aim was to define the differences between vaccinated and un-vaccinated patients in terms of age, comorbidities and course of the disease, and to determine the survival rates. Of the 1463 PCR-positive patients, 55.3 % were vaccinated, and 44.7 % were unvaccinated. While 959 patients had mild-moderate symptoms, 504 patients had severe-critical symptoms and were treated in the intensive care unit. There was a statistically significant difference in the distribution of the type and doses of vaccines between the patient groups (p = 0.021). The rate of receiving 2 doses of Biontech was 18.9 % in the mild-moderate patient group but lower in the severe patient group (12.6 %). The rate of two doses of Sinovac and two doses of Biontech vaccine (four doses of vaccine) was 5 % in the mild-moderate patient group and 1.9 % in the severe patient group. The mortality rates were statistically significantly different (p < 0.001) between the patient groups: 65.3 % in the severe patient group and 1 % in the mild-moderate patient group. The multivariate model showed that the mortality risk of the unvaccinated patients was 1.5 times higher than the vaccinated ones (p = 0.042). In addition to being unvaccinated, advanced age, coronary artery disease (CAD), diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), and obesity were found to be associated with higher mortality risk. Besides, the reduction in mortality rate was more evident in individuals vaccinated with at least 2 doses of the BNT162b2 (Pfizer-BioNTech) vaccine than in CoronaVac group.https://doi.org/10.2478/acph-2023-0020covid-19anti-covid-19 vaccinebnt162b2 (pfizer-biontech)coronavac (sinovac) vaccine efficacy |
| spellingShingle | Dogan Mustafa Yilmaz Berna Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19 Acta Pharmaceutica covid-19 anti-covid-19 vaccine bnt162b2 (pfizer-biontech) coronavac (sinovac) vaccine efficacy |
| title | Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19 |
| title_full | Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19 |
| title_fullStr | Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19 |
| title_full_unstemmed | Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19 |
| title_short | Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19 |
| title_sort | efficacy of bnt162b2 and coronavac in patients diagnosed with covid 19 |
| topic | covid-19 anti-covid-19 vaccine bnt162b2 (pfizer-biontech) coronavac (sinovac) vaccine efficacy |
| url | https://doi.org/10.2478/acph-2023-0020 |
| work_keys_str_mv | AT doganmustafa efficacyofbnt162b2andcoronavacinpatientsdiagnosedwithcovid19 AT yilmazberna efficacyofbnt162b2andcoronavacinpatientsdiagnosedwithcovid19 |